Multivessel Coronary Revascularization Strategies in Patients with Chronic Kidney Disease: A Meta-Analysis.
Early revascularization can lead to better prognosis in multivessel coronary artery disease (CAD) patients with chronic kidney disease (CKD). However, whether coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) is better remains unknown. We searched PubMed and the Cochrane Library database from inception until December 9, 2017, for articles that compare outcomes of CABG and PCI in multivessel CAD patients with CKD. We pooled the odds ratios with a fixed-effects model when I2 < 50% or a random-effects model when I2 > 75% and conducted heterogeneity and quality assessments as well as publication bias analyses. A total of 17 studies with 62,343 patients were included. Compared with CABG, the pooled analysis showed that PCI had a lower risk of short-term all-cause death (OR, 0.56; 95% CI, 0.37-0.84) and cerebrovascular accidents (OR, 0.65; 95% CI, 0.53-0.79) but a higher risk of cardiac death (OR, 1.29; 95% CI, 1.21-1.37), myocardial infarction (MI) (OR, 1.73; 95% CI, 1.35-2.21), and repeat revascularization (RR) (OR, 3.9; 95% CI, 2.99-5.09). There was no significant difference in the risk of long-term all-cause death (OR, 1.08; 95% CI, 0.95-1.23) and major adverse cardiac and cerebrovascular events (MACCE) (OR, 1.58; 95% CI, 0.99-2.52) between the PCI and CABG groups. A subgroup analysis restricted to patients treated with dialysis or with PCI-drug-eluting stent yielded similar results. PCI for patients with CKD and multivessel disease (multivessel CAD) had advantages over CABG with regard to short-term all-cause death and cerebrovascular accidents, but disadvantages regarding the risk of myocardial death, MI, and RR; there was no significant difference in the risk of long-term all-cause death and MACCE. Large randomized controlled trials are needed to confirm our findings.